Piper Jaffray initiated LipoScience LPDX with an Overweight rating rating and a $15.00 price target.
Piper Jaffray noted, "Going forward, we anticipate ongoing traction converting the ~78M domestic LDL-C patient monitoring assays (~$1.8B market) to LDL-P and would note ~11% penetration (in line with North Carolina) represents a ~$330M annual revenue run-rate for LPDX. We believe LipoScience is positioned to meet and potentially beat our forward top and bottom-line projections and we are buyers of LPDX shares at current levels."
LipoScience closed at $11.00 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in